Earnings summaries and quarterly performance for Solventum.
Executive leadership at Solventum.
Bryan Hanson
Detailed
Chief Executive Officer
CEO
Amy Landucci
Detailed
Chief Information & Digital Officer
Chris Barry
Detailed
EVP and Group President, Medical Surgical
Heather Knight
Detailed
Chief Commercial Officer
Marcela Kirberger
Detailed
Chief Legal Affairs Officer and Corporate Secretary
Tammy Gomez
Detailed
Chief Human Resources Officer
Wayde McMillan
Detailed
Chief Financial Officer
Board of directors at Solventum.
Amy Wendell
Detailed
Director
Bernard Harris Jr.
Detailed
Director
Carlos Albán
Detailed
Director
Carrie Cox
Detailed
Chair of the Board
Darryl Wilson
Detailed
Director
Elizabeth Mily
Detailed
Director
Glenn Eisenberg
Detailed
Director
John Weiland
Detailed
Director
Karen May
Detailed
Director
Shirley Edwards
Detailed
Director
Susan DeVore
Detailed
Director
Research analysts who have asked questions during Solventum earnings calls.
Jason Bednar
Piper Sandler Companies
7 questions for SOLV
Also covers: ALGN, COO, EDAP +15 more
Patrick Wood
Morgan Stanley
7 questions for SOLV
Also covers: ALC, BDX, BLCO +17 more
Travis Steed
Bank of America
7 questions for SOLV
Also covers: ABT, AXNX, BAX +19 more
David Roman
Goldman Sachs Group Inc.
4 questions for SOLV
Also covers: ABT, BAX, BDX +18 more
Ryan Zimmerman
BTIG
4 questions for SOLV
Also covers: ALC, GEHC, GKOS +23 more
Steven Valiquette
Mizuho
4 questions for SOLV
Also covers: ALGN, CAH, COR +12 more
Vikramjeet Chopra
Wells Fargo & Company
4 questions for SOLV
Also covers: ALGN, ATEC, CNMD +9 more
Rick Wise
Stifel Financial Corp
3 questions for SOLV
Also covers: BDX, BSX, GEHC +8 more
Christopher Senyek
Wolfe Research
2 questions for SOLV
Also covers: BE, ECG, EVR +2 more
Frederick Wise
Stifel
2 questions for SOLV
Also covers: AORT, ATRC, AVNS +13 more
Vik Chopra
Wells Fargo & Company
2 questions for SOLV
Also covers: ALGN, ATEC, CNMD +7 more
Brett Fishman
KeyBanc Capital Markets Inc.
1 question for SOLV
Also covers: ITGR
Jenny Rabinowitz
Goldman Sachs Group Inc.
1 question for SOLV
Also covers: SYK
Lei Huang
Wells Fargo
1 question for SOLV
Also covers: NVCR, PEN, RXST
Recent press releases and 8-K filings for SOLV.
Solventum reports strong 2025 growth and strategic portfolio actions
SOLV
Revenue Acceleration/Inflection
M&A
Share Buyback
- Solventum delivered six consecutive quarters of positive volume growth, outperformed expectations and raised its 2025 outlook multiple times, progressing ahead of long-range plan sales and margin targets.
- Completed portfolio optimization through the sale of its Purification & Filtration business, which reduced debt and strengthened the balance sheet.
- Announced the strategic acquisition of Acera Surgical to expand its Advanced Wound Care portfolio and launched a $1 billion share repurchase program.
- Advanced the “Transform for the Future” initiative, exiting over 35% of transition service agreements, achieving ERP cutover, and separating supply chain operations to drive cost savings and improve free cash flow.
4 days ago
Solventum acquires Acera and details portfolio transformation strategy
SOLV
M&A
New Projects/Investments
- Solventum will acquire Acera for $725 million upfront, expecting ~$90 million in revenue this year; Acera’s synthetic tissue matrix targets a $900 million acute care wound market growing double‐digits and is accretive to growth and gross margin.
- M&A targets must first meet strategic fit criteria—mission-centric, pathway to leadership, protected technology—then deliver financial accretion to growth, gross/operating margins and ROIC above WACC.
- Completed the purification and filtration divestiture on September 1 and is driving active portfolio optimization via a steady cadence of tuck-in acquisitions, further divestitures and derationalization initiatives.
- Launched a $500 million multi-year restructuring program to optimize systems, consolidate suppliers, enhance automation and redeploy resources as post-3M TSAs wind down.
- Despite a planned 100 bps derationalization headwind in 2026, Solventum expects continued top- and bottom-line organic growth through volume expansion; pricing is viewed as a minor lever within a ±1% normalized range.
Dec 2, 2025, 3:00 PM
Solventum outlines Acera acquisition and portfolio transformation
SOLV
M&A
New Projects/Investments
- Acera acquisition: Solventum’s first deal—a $725 million purchase of synthetic tissue matrix provider Acera, expected to deliver $90 million this year in the $900 million acute care market growing double digits.
- M&A strategy: Focus on “right target, right time, right value,” requiring mission-centric strategic fit (protected, differentiated technology with commercial synergies) and financial fit (ROIC above WACC).
- Portfolio transformation: Committed to ongoing tuck-in M&A and divestitures, having closed its purification filtration divestiture on September 1 before executing Acera, and planning a steady deal cadence.
- Restructuring programs: Completed a $120 million one-year “Solventum Way” initiative and launched a $500 million multi-year program to optimize systems, consolidate suppliers, and reallocate resources.
- Organic growth & pipeline: Targets continued top- and bottom-line expansion in 2026 excluding a 100 bp derationalization headwind; emphasizes volume-driven dental innovation, growing MedSurg pipeline, and potential pre-revenue acquisitions.
Dec 2, 2025, 3:00 PM
Solventum details Acera acquisition and portfolio transformation at Piper Sandler Healthcare Conference
SOLV
M&A
New Projects/Investments
- Announced $725 million acquisition of Acera, a synthetic advanced wound care business expected to deliver $90 million revenue this year with double-digit growth, profitable operations and ROIC above WACC.
- Introduced a $500 million multi-year restructuring program to optimize post-TSAs systems, consolidate suppliers, shift resources to priority areas and enhance operational efficiency.
- Emphasized active portfolio management including tuck-in acquisitions (commercial and pre-commercial) and the recent purification filtration divestiture to focus on core, high-growth assets.
- Forecasted continued top- and bottom-line organic growth in 2026 (ex-100 bps derationalization), driven by operational improvements and product innovation, notably in dental.
- Outlined M&A framework prioritizing mission-centric fit in high-growth markets with protected differentiation and synergies, alongside financial criteria of accretion to growth, margin expansion and ROIC targets.
Dec 2, 2025, 3:00 PM
Solventum announces $1 billion share repurchase program
SOLV
Share Buyback
M&A
- Solventum’s Board approved a $1 billion share buyback authorization to repurchase outstanding common stock
- Repurchases may occur in the open market, through Rule 10b5-1/10b-18 plans or private transactions, with no time limit and subject to market and liquidity conditions
- Repurchases are expected to begin in 2026, with 173.4 million shares outstanding as of October 31, 2025
- The program leverages Solventum’s strong cash generation and healthy balance sheet to support sustainable growth and tuck-in M&A
Nov 20, 2025, 2:00 PM
Solventum announces agreement to acquire Acera Surgical
SOLV
M&A
- Solventum enters a definitive agreement to acquire Acera Surgical for $725 million in cash plus up to $125 million in contingent payments.
- The deal expands Solventum’s MedSurg portfolio into the synthetic tissue matrices market, part of a $900 million U.S. acute care segment.
- Acera is expected to generate approximately $90 million in sales in 2025; the transaction is slightly dilutive to adjusted EPS in 2026 and accretive beginning in 2027.
- The acquisition will be financed with cash on hand (no new debt) and is expected to close in the first half of 2026, subject to customary closing conditions.
Nov 20, 2025, 2:00 PM
Solventum outlines transformation progress and guidance at Stifel 2025 Healthcare Conference
SOLV
Guidance Update
Revenue Acceleration/Inflection
Product Launch
- Transformation ahead of plan: Achieved just over 1% organic sales growth in 2023–2024 and raised 2025 guidance to the high end of 2.5–3.5%, driven by commercial improvements and R&D execution.
- SKU rationalization: Completed a two-wave program removing 8% of global SKUs, improving supply-chain efficiency and avoiding rebranding costs on nearly 10% of products.
- Focused commercial and innovation push: Rolled out specialized sales teams and launched new products—Peel and Place, Prevena (back to double-digit growth), and three sterilization assurance offerings—to drive share gains.
- 2025 Q4 and 2026 outlook: Forecasting ~2.2% organic growth in Q4 and an elevated underlying sales growth rate in 2026, despite a 100 bp headwind from remaining SKU exits.
- Separation and efficiency program: On track to complete 3M TSA roll-offs by end-2026 and initiated a restructuring to offset tariff annualization, stranded costs, and scale-related headwinds.
Nov 12, 2025, 4:20 PM
Solventum reports Q3 2025 results
SOLV
Earnings
Guidance Update
M&A
- Third-quarter sales of $2.1 billion, up 2.7% organically (0.7% reported), driven by volume growth, a 110 bps FX tailwind and a –310 bps impact from the purification & filtration divestiture.
- Segment performance: Med-Surg sales of $1.2 B (+1.1% organic; advanced wound care +2.7% led by double-digit Prevena; infection prevention flat), Dental Solutions $340 M (+6.5%), HIS $345 M (+5.6%).
- Gross margin of 55.8% (–20 bps sequential) and adjusted operating margin of 20.6% (adjusted operating income of $431 M); earnings per share of $1.50.
- Balance sheet strengthened by $3.6 B net proceeds from the P&F sale, $2.7 B of debt paydown, ending Q3 with $1.6 B in cash and no revolver borrowings; YTD free cash flow ex-divestiture of $735 M (93% conversion).
- Raised full-year organic sales growth guidance to the high end of 2–3%; EPS guidance to $5.98–$6.08; FY free cash flow of $150–250 M (incl. P&F) or $450–550 M ex-P&F; launched four-year “Transform for the Future” program targeting $500 M in annual savings.
Nov 6, 2025, 9:30 PM
Solventum reports Q3 2025 results
SOLV
Earnings
Guidance Update
M&A
- Third-quarter sales were $2.1 billion, up 2.7% organically and 0.7% on a reported basis.
- Delivered adjusted EPS of $1.50, with an effective tax rate of 21.8%.
- Paid down $2.7 billion of debt in Q3, ending the quarter with $1.6 billion in cash and no revolver borrowings.
- Raised full-year guidance: organic sales growth to 2–3%, EPS to $5.98–$6.08, and free cash flow to $150 million–$250 million (or $450 million–$550 million excluding the purification and filtration divestiture).
- Announced a four-year “Transform for the Future” program projected to deliver $500 million in annual savings at a cost of $500 million, and will pursue tuck-in M&A deals under $1 billion.
Nov 6, 2025, 9:30 PM
Solventum reports Q3 2025 results
SOLV
Earnings
Guidance Update
- Solventum delivered $2.1 billion in Q3 2025 sales, up 2.7% organic and 0.7% reported, with MedSurg up 1.1% and Dental and HIS exceeding expectations.
- Q3 gross margin was 55.8% with operating margin at 20.6%, driving $1.50 EPS; net interest expense improved and effective tax rate was 21.8%.
- Raised full-year 2025 guidance: organic sales now at the high end of +2.5%–3.5%, EPS to $5.98–$6.08, and free cash flow to $150–$250 million (or $450–$550 million ex-P&F divestiture).
- Strengthened balance sheet with $3.6 billion net divestiture proceeds, $1.6 billion cash, and $2.7 billion debt paydown; launched “Transform for the Future” to deliver $500 million in annual savings over four years at a $500 million investment.
Nov 6, 2025, 9:30 PM
Quarterly earnings call transcripts for Solventum.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more